{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:18:08Z","timestamp":1790842688441,"version":"4.1.0"},"reference-count":59,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:00:00Z","timestamp":1511740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["SPORE CA100632"],"award-info":[{"award-number":["SPORE CA100632"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ruxolitinib and azacytidine target distinct disease manifestations of myelodysplastic syndrome\/myeloproliferative neoplasms (MDS\/MPNs). Patients with MDS\/MPNs initially received ruxolitinib BID (doses based on platelets count), continuously in 28\u2010day cycles for the first 3 cycles. Azacytidine 25 mg\/m<jats:sup>2<\/jats:sup> (Day 1\u20105) intravenously or subcutaneously was recommended to be added to each cycle starting cycle 4 and could be increased to 75 mg\/m<jats:sup>2<\/jats:sup> (Days 1\u20105) for disease control. Azacytidine could be started earlier than cycle 4 and\/or at higher dose in patients with rapidly proliferative disease or with elevated blasts. Thirty\u2010five patients were treated (MDS\/MPN\u2010U, <jats:italic>n<\/jats:italic> =14; CMML, <jats:italic>n<\/jats:italic> =17; aCML, <jats:italic>n<\/jats:italic> =4), with a median follow\u2010up of 15.2 months (range, 1.0\u201341.5). All patients were evaluable by the 2015 international consortium proposal of response criteria for MDS\/MPNs (ICP MDS\/MPN) and 20 (57%) responded. Nine patients (45%) responded after the addition of azacytidine. A greater than 50% reduction in palpable splenomegaly at 24 weeks was noted in 9\/14 (64%) patients. Responders more frequently were <jats:italic>JAK2<\/jats:italic>\u2010mutated (<jats:italic>P<\/jats:italic>\u2009=\u2009.02) and had splenomegaly (<jats:italic>P<\/jats:italic>\u2009=\u2009.03) compared to nonresponders. New onset grade 3\/4 anemia and thrombocytopenia occurred in 18 (51%) and 19 (54%) patients, respectively, but required therapy discontinuation in only 1 (3%) patient. Patients with MDS\/MPN\u2010U had better median survival compared to CMML and aCML (26.5 vs 15.1 vs 8 months; <jats:italic>P<\/jats:italic>\u2009=\u2009.034). The combination of ruxolitinib and azacytidine was well\u2010tolerated with an ICP MDS\/MPN\u2010response rate of 57% in patients with MDS\/MPNs. The survival benefit was most prominent in patients with MDS\/MPN\u2010U.<\/jats:p>","DOI":"10.1002\/ajh.24972","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T08:32:36Z","timestamp":1510648356000},"page":"277-285","source":"Crossref","is-referenced-by-count":75,"title":["A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms"],"prefix":"10.1002","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0046-7113","authenticated-orcid":false,"given":"Rita","family":"Assi","sequence":"first","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Nogueras\u2010Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"Dinardo","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Bueso\u2010Ramos","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingsha","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romany","family":"Gergis","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajyalakshmi","family":"Luthra","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-5837","authenticated-orcid":false,"given":"Juliana","family":"Hidalgo\u2010Lopez","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"47","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe ESHN","year":"2001"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.114660"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.119"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.164"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.337"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.3314"},{"key":"e_1_2_8_10_1","unstructured":"BoseP AN RK et al. Mutational landscape of myelodysplastic syndrome\/myeloproliferative neoplasm\u2010 unclassifiable (MDS\/MPN\u2010U) EHA Learning Center.2017;181639."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.133"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-579466"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26741"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.8"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-553800"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-1019-9"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.6.1896"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-320069"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115840"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117"},{"key":"e_1_2_8_23_1","first-page":"121","article-title":"Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO\u2010defined acute myeloid leukaemia compared with conventional care regimens: an update","volume":"2","author":"Fenaux P","year":"2008","journal-title":"Ecancermedicalscience."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352039"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30814"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22457"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.730615"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24396"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.986477"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-693630"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.91"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.136"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-274811"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-293415"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.093765"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-607341"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780140404"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23697"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2781"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214514"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2014.07.002"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.148"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1502524"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30558-7"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1217528"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.01.004"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119545"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633404"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.119"},{"key":"e_1_2_8_54_1","first-page":"40","article-title":"Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes","volume":"8","author":"Cogle CR","year":"2010","journal-title":"Clin Adv Hematol Oncol."},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.86"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.134"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.173"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.86"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.10.027"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.07.004"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24972","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T18:14:29Z","timestamp":1694715269000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,27]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/ajh.24972"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24972","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,27]]}}}